Troglitazone: An antidiabetic agent

American Journal of Health-System Pharmacy

Volumn 55, Issue 9, 1998, Pages 905-925

  Chen, Connie ^a  

^a University HealthSystem Consortium   (United States)

Author keywords

Antidiabetic agents; Combined therapy; Costs; Diabetes mellitus; Dosage; Drug interactions; Insulins; Mechanism of action; Pharmacokinetics; Sulfonylureas; Toxicity; Troglitazone

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ALCOHOL; CHLORPROPAMIDE; COLESTYRAMINE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; SULFONYLUREA DERIVATIVE; TERFENADINE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE; WARFARIN;

DIABETES MELLITUS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; GLUCONEOGENESIS; GLYCOLYSIS; HEMATOLOGIC DISEASE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0032080751     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.9.905     Document Type: Review

References (61)

1. Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care. 1992; 15:1075-8.
2. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996; 45: 1661-9.
3. Shamoon H. Pathophysiology of diabetes: a review of selected recent developments and their impact on treatment. Drugs. 1992; 44(suppl 3):1-12.
4. Cefalu WT. Treatment of type II diabetes. Postgrad Med. 1996; 99:109-22.
5. Keen H. Insulin resistance and the prevention of diabetes mellitus. N Engl J Med. 1994; 331:1226-7.
6. Colca JR. Potential antidiabetic drugs affecting the sensitivity of tissues to insulin. Exp Opin Invest Drugs. 1994; 3:857-60.
7. Nolan JJ, Ludvik B, Beerdsen P et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994; 331:1188-93.
8. Donnelly R, Morris AD. Drugs and insulin resistance: clinical methods of evaluation and new pharmacological approaches to metabolism. Br J Clin Pharmacol. 1994; 37:311-20.
9. Mediratta S, Fozailoff A, Frishman WH. Insulin resistance in systemic hypertension: pharmacotherapeutic implications. J Clin Pharmacol. 1995; 35:943-56.
10. Colca JR. Insulin sensitizer drugs in development for the treatment of diabetes. Exp Opin Invest Drugs. 1995; 4:27-9.
11. Suter SL, Nolan JJ, Wallace P et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992; 15:193-203.
12. Whitcomb RW, Saltiel AR. Thiazolidinediones. Exp Opin Invest Drugs. 1995; 4:1299-309.
13. Cantello BCC, Cawthorne MA, Haigh D et al. The synthesis of BRL 49653: a novel and potent antihyperglycaemic agent. Bioorg Med Chem. 1994; 4:1181-4.
14. Rezulin package insert. Morris Plains, NJ: Parke-Davis; 1997.
15. Sankyo/Parke-Davis joint venture to promote Accupril ACE inhibitor and troglitazone antidiabetic; provides platform for future Sankyo launches in U.S. FDC Rep. 1996; 58(Sep 30):7-8.
16. 16: Nagasaka Y, Kaku K, Nakamura K et al. The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low-density lipoprotein in vitro. Biochem Pharmacol. 1995; 50:1109-11.
17. Noguchi N, Sakai H, Kato Y et al. Inhibition of oxidation of low-density lipoprotein by troglitazone. Atherosclerosis. 1996; 123:227-34.
18. Cominacini L, Garbin U, Fratta Pasini A et al. Troglitazone increases the resistance of LDL to oxidation in healthy volunteers. Diabetologia. 1996; 39(suppl A)885:A233. Abstract.
19. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996; 334:374-81.
20. Ogihara T, Rakugi H, Ikegami H et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995; 8:316-20.
21. Kotchen TA. Attenuation of hypertension by insulin-sensitizing agents. Hypertension. 1996; 28:219-23.
22. Shibata H, Nii S, Kobayshi M et al. Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers: safety and pharmacokinetics in single administration. Rinsho Iyaku. 1993; 9:1503-18.
23. Young MA, Robinson CE, Devoy MAB et al. The influence of food on the pharmacokinetics of GR92132X, a thiazolidinedione, in healthy subjects. Br J Clin Pharmacol. 1994; 37:482 P. Abstract.
24. Young MA, Williams ZV, Eastmond R. Similar pharmacokinetics of troglitazone in young and elderly subjects. Diabetologia. 1996; 39(suppl A)882:A233. Abstract.
25. Kumar S, Boulton AJM, Beck-Nielsen H et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 1996; 39:701-9.
26. Iwamoto Y, Kosaka K, Kuzuya T et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996; 19:151-6.
27. Kuzuya T, Iwamoto Y, Kosaka K et al. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1991; 11:146-54.
28. Onuma T, Tsutsui M, Goto T et al. The effect of a new oral hypoglycemic drug, CS-045, on glucose tolerance and serum lipids in nonobese Japanese patients with non-insulin-dependent diabetes mellitus: a pilot study. Curr Ther Res. 1994; 55:416-21.
29. Iwamoto Y, Kuzuya T, Matsuda A et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 1991; 14:1083-6.
30. Mimura K, Umeda F, Hiramatsu S et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type II diabetes. Diabet Med. 1994; 11:685-91.
31. Foot EA, Patel J, Williams ZV et al. Improved metabolic control by addition of troglitazone to glibenclamide therapy in non-insulin-dependent diabetics. Diabetologia. 1995; 38(suppl 1):A44. Abstract.
32. Iwamoto Y, Kuzuya T, Fujita N et al. Effect of CS-045 (troglitazone) in patients with NIDDM. In: Sakamoto N, Alberti KGMM, Hotta N, eds. Pathogenesis and treatment of NIDDM and its related problems. New York: Elsevier Science B.V.; 1994:313-7.
33. Dunaif A, Scott D, Finegood D et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996; 81:3299-306.
34. Berkowitz K, Peters R, Kjos S et al. Effects of troglitazone on insulin sensitivity and B-cell function in women with prior gestational diabetes. Diabetes. 1996; 45(suppl 2):206. Abstract.
35. Takino H, Okuno S, Uotani S et al. Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome. Diabetes Res Clin Pract. 1994; 24:167-72.
36. Deems RO. The 15th International Diabetes Federation: meeting highlights. Exp Opin Invest Drugs. 1995; 4:159-61.
37. Antonucci T, Whitcomb R, McLain R et al. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care. 1997; 20:188-93.
38. Valiquett T, Balagtas C, Whitcomb R. Troglitazone dose-response study in patients with NIDDM. Diabetes. 1995; 44(suppl 1):109A. Abstract.
39. Hansen AP. Effects of troglitazone, a thiazolidinedione, in elderly non-insulin-dependent diabetic patients. Diabetologia. 1995; 38(suppl 1):A200. Abstract.
40. Ghazzi MN, Perez JE, Antonucci TK et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 1997; 46:433-9.
41. Iwamoto Y, Kosaka K, Kuzuya T et al. Effect of combination therapy of troglitazone and sulphonylureas in patients with type II diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med. 1996; 13:365-70.
42. Akanuma Y, Kosaka K, Toyoda T et al. Clinical evaluation of a new oral hypoglycemic agent CS-045 in combination with insulin. Diabetologia. 1996; 39(suppl 1)232:A881. Abstract.
43. Bloomgarden ZT. New and traditional treatment of glycemia in NIDDM. Diabetes Care. 1996; 19:295-9.
44. Wolffenbuttel BHR, Graal MB. New treatments for patients with type II diabetes mellitus. Postgrad Med J. 1996; 72:657-62.
45. Warner-Lambert Rezulin sNDA for broad type II diabetes indication will be filed shortly; phase IV study will look at volume expansion in severe CHF patients. FDC Rep. 1997; 58(Feb 3):7-8.
46. Püchler K, Sasahara K, Witte PU et al. Lack of pharmacokinetic interaction between troglitazone and glibenclamide in NIDDM patients. Diabetologia. 1996; 39(suppl 1)232:A880. Abstract.
47. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.
48. Henry RR. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124:97-103.
49. Stephenson J. Preventing type II diabetes? JAMA. 1996; 276:182.
50. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 1994; 11:223-41.
51. Wolffenbuttel BHR, van Haeften TW. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Drugs. 1995; 50:263-88.
52. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs. 1995; 49:721-49.
53. Toeller M. α-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Invest. 1994; 24(suppl 3):31-5.
54. Lebovitz HE. Oral antidiabetic agents: the emergence of α-glucosidase inhibitors. Drugs. 1992; 44(suppl 3):21-8.
55. Bailey CJ. Diabetes control: treating a moving target. Intern Med. 1996; 17(11):90-101.
56. Garber AJ, Gavin JR, Goldstein BJ. Understanding insulin resistance and syndrome X. Patient Care. 1996; 30:198-211.
57. Cefalu W, Colwell J, King GE. What's new about the new oral diabetes drugs? Patient Care. 1996; 30:40-66.
58. Rezulin (troglitazone) package insert. Morris Plains, NJ: Parke-Davis; 1997 Dec.
59. Ghazzi M, Radke-Mitchell E, Venable T, Whitcomb R. Troglitazone improves glycemic control in patients with type 2 diabetes who are not optimally controlled on sulfonylurea. Diabetes. 1997; 46(suppl 1):P44A, 0169. Abstract.
60. Warner-Lambert Rezulin arm in NIH diabetes prevention trial is being retained; Glaxo troglitazone withdrawal in U.K. prompts re-evaluation of U.S. status. FDC Rep. 1997; 59(49):5-6.
61. Segal M. Patient testing and labeling strengthened for Rezulin. (FDA Talk Paper T97-61.) http://www.fda.gov/bbs/topics/ANSWERS/ANS00837.html (accessed January 19, 1998).